AR043254A1 - Metodo para determinar la cantidad de sustancia bloqueante neuromuscular pre-sinaptica contenida en una muestra - Google Patents
Metodo para determinar la cantidad de sustancia bloqueante neuromuscular pre-sinaptica contenida en una muestraInfo
- Publication number
- AR043254A1 AR043254A1 ARP040100547A ARP040100547A AR043254A1 AR 043254 A1 AR043254 A1 AR 043254A1 AR P040100547 A ARP040100547 A AR P040100547A AR P040100547 A ARP040100547 A AR P040100547A AR 043254 A1 AR043254 A1 AR 043254A1
- Authority
- AR
- Argentina
- Prior art keywords
- neuromuscular blocking
- sample
- blocking substance
- synaptic neuromuscular
- determining
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/944—Acetylcholine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Método para determinar la cantidad de sustancia bloqueante neuromuscular pre-sináptica (especialmente toxina botulínica) contenida en una muestra. En un aspecto, el método comprende los siguientes pasos: i) determinar el voltaje mínimo Vm necesario para inducir la contracción del tejido muscular, estando dicho tejido muscular conectado a un estimulador eléctrico a través de un nervio motor y con preferencia sumergido en un buffer fisiológico oxigenado que contiene glucosa; ii) agregar la muestra que contiene la sustancia bloqueante neuromuscular pre-sináptica; iii) estimular eléctricamente, a un voltaje al menos igual a Vm el tejido muscular a ciertos intervalos de tiempo; iv) comparar el efecto inducido por la muestra al efecto inducido por una sustancia de referencia y, de ese modo, determinar al cantidad de sustancia bloqueante neuromuscular pre-sináptica contenida en la muestra. Reivindicación 19: El método de cualquiera de las reivindicaciones de 1 a 14, en el cual la sustancia bloqueante neuromuscular pre-sináptica es un bungarotoxina. Reivindicación 21: Un método para determinar la cantidad de anticuerpos neutralizantes de una sustancia bloqueante neuromuscular pre-sináptica en una muestra, que comprende los siguientes pasos: i) determinar el voltaje mínimo de Vm necesario para inducir la contracción del tejido muscular, estando dicho tejido muscular conectado a un estimulador eléctrico a través de un nervio motor; ii) agregar una mezcla de la muestra a ensayar que contiene los anticuerpos neutralizantes de la sustancia bloqueante neuromuscular pre-sináptica y una cantidad determinada de dicha sustancia bloqueante neuromuscular pre-sináptica, habiéndose pre-incubado dicha muestra a una temperatura de 0 a 45° C por un período de aproximadamente 15 a 120 minutos; iii) estimular eléctricamente, a un voltaje al menos igual a Vm el tejido muscular a ciertos intervalos de tiempo; iv) comparar el efecto inducido por la mezcla al efecto inducido por una determinada cantidad de dicha sustancia bloqueante neuromuscular pre-sináptica y, de ese modo, determinar la cantidad de anticuerpos neutralizantes de la sustancia bloqueante neuromuscular pre-sináptica contenida en la muestra.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0303997A GB2398636A (en) | 2003-02-21 | 2003-02-21 | Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample |
Publications (1)
Publication Number | Publication Date |
---|---|
AR043254A1 true AR043254A1 (es) | 2005-07-20 |
Family
ID=9953431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040100547A AR043254A1 (es) | 2003-02-21 | 2004-02-20 | Metodo para determinar la cantidad de sustancia bloqueante neuromuscular pre-sinaptica contenida en una muestra |
Country Status (15)
Country | Link |
---|---|
US (1) | US8877456B2 (es) |
EP (1) | EP1597584B1 (es) |
JP (2) | JP2006518211A (es) |
KR (1) | KR101161879B1 (es) |
CN (1) | CN100401069C (es) |
AR (1) | AR043254A1 (es) |
AT (1) | ATE378602T1 (es) |
AU (1) | AU2004213639B2 (es) |
CA (1) | CA2516377A1 (es) |
DE (1) | DE602004010073T2 (es) |
GB (1) | GB2398636A (es) |
NZ (1) | NZ541853A (es) |
PL (1) | PL377994A1 (es) |
RU (1) | RU2350961C2 (es) |
WO (1) | WO2004074838A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201708749T4 (tr) | 2004-08-04 | 2018-03-21 | Ipsen Biopharm Ltd | Botuli̇num nörotoksi̇n a2 i̇çeren farmasöti̇k bi̇leşi̇m |
EP1778279B1 (en) | 2004-08-04 | 2014-12-03 | Ipsen Biopharm Limited | Pharmaceutical composition containing botulinum neurotoxin a2 |
GB2416849A (en) | 2004-08-04 | 2006-02-08 | Ipsen Ltd | Method for determining the quantity of a pre-synaptic neuromuscular blocking substance in a sample |
US7473559B2 (en) * | 2006-04-05 | 2009-01-06 | Charles Lee | Method for measuring the content of a botulinum toxin in a formulation |
EP2202518A1 (en) | 2008-12-19 | 2010-06-30 | Merz Pharma GmbH & Co.KGaA | In vivo assay for quantifying clostridial neurotoxin activity |
MX2012005496A (es) | 2009-11-18 | 2012-06-14 | Merz Pharma Gmbh & Co Kgaa | Ensayo para cuantificar neorotoxina clostridial. |
SI2761065T1 (en) | 2011-09-29 | 2018-02-28 | Cellsnap, Llc | Ingredients and procedures for toxicity testing |
MX360513B (es) | 2013-06-28 | 2018-11-07 | Merz Pharma Gmbh & Co Kgaa | Medios y metodos para la determinacion de la actividad biologica de polipeptidos de neurotoxina en celulas. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5251621A (en) * | 1991-12-18 | 1993-10-12 | Telectronics Pacing Systems, Inc. | Arrhythmia control pacer using skeletal muscle cardiac graft stimulation |
US5631373A (en) | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
US5591217A (en) * | 1995-01-04 | 1997-01-07 | Plexus, Inc. | Implantable stimulator with replenishable, high value capacitive power source and method therefor |
SE9603841D0 (sv) | 1996-10-18 | 1996-10-18 | Pacesetter Ab | A tissue stimulating apparatus |
ES2385130T3 (es) * | 1997-07-15 | 2012-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Uso de terapia con neurotoxinas para el tratamiento de enfermedades urológicas y de enfermedades relacionadas |
-
2003
- 2003-02-21 GB GB0303997A patent/GB2398636A/en not_active Withdrawn
-
2004
- 2004-02-20 AU AU2004213639A patent/AU2004213639B2/en not_active Ceased
- 2004-02-20 WO PCT/GB2004/000697 patent/WO2004074838A1/en active IP Right Grant
- 2004-02-20 CA CA002516377A patent/CA2516377A1/en not_active Abandoned
- 2004-02-20 CN CNB2004800046866A patent/CN100401069C/zh not_active Expired - Fee Related
- 2004-02-20 US US10/545,009 patent/US8877456B2/en not_active Expired - Fee Related
- 2004-02-20 NZ NZ541853A patent/NZ541853A/en not_active IP Right Cessation
- 2004-02-20 AR ARP040100547A patent/AR043254A1/es active IP Right Grant
- 2004-02-20 PL PL377994A patent/PL377994A1/pl not_active Application Discontinuation
- 2004-02-20 RU RU2005129338/15A patent/RU2350961C2/ru not_active IP Right Cessation
- 2004-02-20 JP JP2006502311A patent/JP2006518211A/ja not_active Withdrawn
- 2004-02-20 AT AT04713111T patent/ATE378602T1/de not_active IP Right Cessation
- 2004-02-20 EP EP04713111A patent/EP1597584B1/en not_active Revoked
- 2004-02-20 DE DE602004010073T patent/DE602004010073T2/de not_active Expired - Lifetime
- 2004-02-20 KR KR1020057015360A patent/KR101161879B1/ko not_active IP Right Cessation
-
2011
- 2011-07-21 JP JP2011160053A patent/JP2011254825A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
GB2398636A (en) | 2004-08-25 |
CN1751238A (zh) | 2006-03-22 |
US20060263352A1 (en) | 2006-11-23 |
CA2516377A1 (en) | 2004-09-02 |
WO2004074838A1 (en) | 2004-09-02 |
GB0303997D0 (en) | 2003-03-26 |
JP2011254825A (ja) | 2011-12-22 |
EP1597584A1 (en) | 2005-11-23 |
ATE378602T1 (de) | 2007-11-15 |
EP1597584B1 (en) | 2007-11-14 |
AU2004213639B2 (en) | 2010-04-29 |
AU2004213639A1 (en) | 2004-09-02 |
RU2350961C2 (ru) | 2009-03-27 |
DE602004010073D1 (de) | 2007-12-27 |
JP2006518211A (ja) | 2006-08-10 |
NZ541853A (en) | 2007-02-23 |
RU2005129338A (ru) | 2006-06-10 |
DE602004010073T2 (de) | 2008-09-11 |
CN100401069C (zh) | 2008-07-09 |
KR20050113184A (ko) | 2005-12-01 |
KR101161879B1 (ko) | 2012-07-05 |
PL377994A1 (pl) | 2006-02-20 |
US8877456B2 (en) | 2014-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Graven-Nielsen et al. | The peripheral apparatus of muscle pain: evidence from animal and human studies | |
Copp et al. | The mechano‐gated channel inhibitor GsMTx4 reduces the exercise pressor reflex in decerebrate rats | |
Tesch et al. | Skeletal muscle proteolysis in response to short-term unloading in humans | |
Fuchs et al. | Sensitized peripheral nociception in experimental diabetes of the rat | |
Gustafsson et al. | Effects of 3 days unloading on molecular regulators of muscle size in humans | |
Xian-Min et al. | Response properties and descending control of rat dorsal horn neurons with deep receptive fields | |
Sauer et al. | Rat peripheral nerve components release calcitonin gene-related peptide and prostaglandin E2 in response to noxious stimuli: evidence that nervi nervorum are nociceptors | |
Phillis et al. | Vasoactive intestinal polypeptide excitation of central neurons | |
Caiozzo et al. | Influence of mechanical loading on myosin heavy-chain protein and mRNA isoform expression | |
Cholewa et al. | Basic models modeling resistance training: an update for basic scientists interested in study skeletal muscle hypertrophy | |
Simonetta‐Moreau et al. | The pattern of excitation of human lower limb motoneurones by probable group II muscle afferents | |
Nó et al. | Decremental conduction in peripheral nerve. Integration of stimuli in the neuron | |
DE3587892D1 (de) | Automatische Injektionseinrichtung. | |
AR043254A1 (es) | Metodo para determinar la cantidad de sustancia bloqueante neuromuscular pre-sinaptica contenida en una muestra | |
Johansson et al. | Predictors for the outcome of treatment with high frequency transcutaneous electrical nerve stimulation in patients with chronic pain | |
Oh et al. | Chemical communication between vagal afferent somata in nodose Ganglia of the rat and the Guinea pig in vitro | |
Aguayo et al. | One bout of vibration exercise with vascular occlusion activates satellite cells | |
Harridge et al. | Training by low‐frequency stimulation of tibialis anterior in spinal cord–injured men | |
Liebano et al. | Effect of low‐frequency transcutaneous electrical nerve stimulation (TENS) on the viability of ischemic skin flaps in the rat: An amplitude study | |
BR9906926A (pt) | Composições e métodos para tratamento de células tendo dna de minuto duplo | |
Calvino et al. | Dorsal horn (convergent) neurones in the intact anaesthetized arthritic rat. II. Heterotopic inhibitory influences | |
Yoshikawa et al. | Effects of combined treatment with blood flow restriction and low-current electrical stimulation on muscle hypertrophy in rats | |
Fazalbhoy et al. | Tonic muscle pain does not increase fusimotor drive to human leg muscles: implications for chronic muscle pain | |
Mori et al. | Electro-acupuncture stimulation to a hindpaw and a hind leg produces different reflex responses in sympathoadrenal medullary function in anesthetized rats | |
Hamamoto et al. | Characterization of cutaneous primary afferent fibers excited by acetic acid in a model of nociception in frogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |